Clinical Trial Update: A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase II trial comparing venetoclax plus fulvestrant versus fulvestrant alone in ER+/HER2-negative locally advanced or metastatic breast cancer after progressio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-09-27